CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 26, 2013--
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a biotechnology company
developing Toll-like receptor targeted drug candidates for the treatment
of autoimmune diseases, today announced a presentation of preclinical
data will be made by its collaborator, Dr. James G. Krueger of The
Rockefeller University, at the Late-Breaking Research Symposium during
the American Academy of Dermatology Annual Meeting being held March 1st
through 5th, 2013, in Miami Beach, Florida.
The details of the presentation are as follows:
Title: Novel Toll-Like Receptor Antagonists Strongly Decrease
Expression of IL-23-induced and Psoriasis Profile Genes in a Mouse Model
Date: Saturday, March 2nd, 2013, at 10:00 am ET
Session: Late Breaking Research Symposium
About Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals applies its proprietary Toll-like receptor (TLR)
drug discovery platform to create immunomodulatory drug candidates and
has a clinical development program in autoimmune diseases. Additionally,
Idera has a collaboration with Merck & Co. for the use of TLR-targeted
candidates as vaccine adjuvants for cancer, infectious diseases and
Alzheimer’s disease. The Company is also exploring its gene-silencing
oligonucleotide (GSO) technology for the purpose of inhibiting the
expression of disease-promoting genes. For more information, visit http://www.iderapharma.com.
Idera Forward Looking Statements
This press release contains forward-looking statements concerning Idera
Pharmaceuticals, Inc. that involve a number of risks and uncertainties.
For this purpose, any statements contained herein that are not
statements of historical fact may be deemed to be forward-looking
statements. Without limiting the foregoing, the words "believes,"
"anticipates," "plans," "expects," "estimates," "intends," "should,"
"could," "will," "may," and similar expressions are intended to identify
forward-looking statements. There are a number of important factors that
could cause Idera's actual results to differ materially from those
indicated by such forward-looking statements, including whether Idera’s
cash resources will be sufficient to fund the Company’s continuing
operations and the further development of the Company’s autoimmune
disease program; whether results obtained in preclinical studies and
early clinical trials will be indicative of results obtained in future
clinical trials; whether products based on Idera's technology will
advance into or through the clinical trial process on a timely basis or
at all and receive approval from the United States Food and Drug
Administration or equivalent foreign regulatory agencies; whether, if
the Company's products receive approval, they will be successfully
distributed and marketed; whether the Company will be able to license
any of its TLR target candidates on a timely basis or at all; whether
the Company's collaboration with Merck & Co, Inc., will be successful;
whether the patents and patent applications owned or licensed by the
Company will protect the Company's technology and prevent others from
infringing it; and such other important factors as are set forth under
the caption "Risk Factors" in Idera's Quarterly Report on Form 10-Q for
the quarter ended September 30, 2012 which important factors are
incorporated herein by reference. Idera disclaims any intention or
obligation to update any forward-looking statements.
Source: Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc.
Lou Arcudi, 617-679-5517